TABLE 1.

Adherence to testing among total population, results of recommended bloodwork for nonalcoholic fatty liver disease, and associated costs of assays

Test	Total* N = 95, n (%)	Abnormal Bloodwork,† n (%)	Abnormal Bloodwork Resulting in Diagnoses,‡ n (%)	Estimated Abnormal Results, n (95% CI)§	Cost (CAD$)∥
HepC Ab	44 (46.3)	1 (2.3)	1 (2.3)	2.2 (2.1–2.3)	15.00
HepA IgM	18 (18.9)	1 (5.6)	1 (5.6)	5.3 (5.2–5.5)	15.00
HepBS Ag	51 (53.7)	2 (3.9)	1 (2.0)	3.7 (3.6–3.8)	15.00
LAL	2 (2.1)	0 (0)	0	0	75.00
A1AT	50 (52.6)	2 (4.0)	1 (2.0)	3.8 (3.7–4.0)	150.00
ANA	60 (63.2)	7 (11.7)	1 (1.7)	11.1 (11.0–11.2)	22.75
ASMA	54 (56.8)	0 (0)	0	0	25.00
anti–LKM-1	53 (55.8)	0 (0)	0	0	27.75
Ceruloplasmin	52 (54.7)	0 (0)	0	0	6.30
IgG	65 (68.4)	1 (1.5)¶	0	1.5 (1.4–1.6)	2.50
IgA	65 (68.4)	1 (1.5)#	0	1.5 (1.4–1.6)	2.50
TTG-IgA	52 (54.7)	6 (11.5)	4 (7.7)	11.0 (10.9–11.2)	31.50
TSH	58 (61.1)	6 (10.3)	2 (3.4)	9.8 (9.7–10.0)	9.00

A1AT = alpha 1 antitrypsin; AMA = anti-mitochondrial antibody; ANA = antinuclear antibody; anti-LKM-1 = liver kidney microsome type 1 antibody; ASMA = anti-smooth muscle antibody; CAD = Canadian dollar; CI, confidence interval; HepA IgM = hepatitis A immunoglobulin M; HepBS Ag = hepatitis B surface antigen; HepC Ab = hepatitis C antibody; LAL = lysosomal acid lipase; TSH = thyroid-stimulating hormone; TTG-IgA = tissue transglutaminase immunoglobulin A.

*Patients who had testing performed across total study population.

†Patients with positive results among those who were tested.

‡Patients with diagnoses pending not included.

§Number of patients estimated to have positive results if testing was performed across the total study population.

∥Charges for phlebotomist and laboratory technician time not included.

¶IgG greater than the upper limit of normal for age.

#IgA less than the lower limit of normal for age.